Related items

Europe’s life sciences sector sits at the heart of the EU’s competitiveness agenda. It supports advanced manufacturing and helps bring new treatments and technologies to patients. Yet companies deciding where to invest need a regulatory environment that is predictable and open to global cooperation. 

The European Commission’s work on the Biotech Act and the targeted revision of the Medical Devices and In Vitro Diagnostics Regulations (MDR/IVDR) offers an opportunity to improve that environment. Both files can help make Europe a stronger location for life sciences investment. 

The EU should use this moment to build a framework that keeps pace with scientific progress. That means faster and clearer procedures. It also means better use of data and intellectual property rules that recognise the realities of global supply chains. 

Today, the European Parliament adopted its Omnibus VI report, including the revision of the Classification, Labelling and Packaging (CLP) Regulation, by 540 votes to 60. The outcome supports a more streamlined framework by easing the regulatory burden on value chains that rely on chemicals and sending a positive signal of the EU’s commitment to reducing unnecessary complexity.

With the Council’s position agreed in November 2025, the Parliament’s report marks the final step before trilogues, which will conclude negotiations on the targeted revision of the CLP Regulation.

The report largely aligns with the Commission’s simplification agenda and strengthens the CLP Regulation’s overall workability, especially with regards to:

• Transition periods, setting 18 months following classification updates and allowing digital contact information to be updated on the label in line with suppliers’ regular update cycles. This better reflects supply chain realities.

• Advertising and distance sales requirements, appropriately excluding business-to-business settings while ensuring consumers remain protected; and

• Label legibility requirements, with more proportionate minimum font sizes and rules on background contrast, spacing and overall layout. However, further simplification is still needed to ensure sufficient flexibility for businesses.

While the report represents a constructive step forward, trilogues should address remaining constraints and clarify language that is currently difficult to interpret, including further simplification on font sizes and advertising requirements in business-to-consumer settings. These negotiations should draw on the more proportionate approaches of the Commission and the Council.

Maintaining a strong focus on simplification will be key to further alleviating administrative burdens and strengthening the EU’s resilience and competitiveness.

On 8 July 2025, the Commission presented the Omnibus VI simplification package, reopening key legislation such as the CLP Regulation, which entered into force in December 2024. The Omnibus addresses overlaps and inconsistencies that create practical challenges and, in some cases, make compliance unworkable.

Upcoming trilogues can streamline the framework and reduce unnecessary burdens. This paper sets out targeted recommendations on the positions that can achieve meaningful simplification during the inter-institutional negotiations.